Abstract
Background: Darbepoetin alfa (darbepoetin) is an erythropoiesis-stimulating agent used for the treatment of anemia secondary to chronic kidney disease (CKD) in dogs, but reports describing response are lacking. Hypothesis/Objectives: To evaluate the effectiveness of darbepoetin in dogs with anemia secondary to CKD, dosing protocols, and adverse events. Animals: Thirty-three client-owned dogs with naturally occurring CKD, including 26 with comorbidities. Methods: Multi-institutional retrospective study. Results: The median starting dosage and highest dosage of darbepoetin administered were 0.5 and 0.8 μg/kg SC once weekly, respectively. Response to treatment was defined as achieving a packed cell volume (PCV) ≥30% or an increase in PCV ≥10%. Twenty-eight of 33 dogs (85%) achieved a PCV ≥30% and 22 of 33 (67%) dogs achieved an increase in PCV ≥10%. Median time to achieve a PCV ≥30% was 29 days. A higher starting dosage was associated with achieving an increase in PCV ≥10% (P =.01). No dog sustained a response at a dosing interval >q21d. Potential adverse events included increased blood pressure requiring treatment (n = 12), seizures (n = 5), vomiting (n = 3), diarrhea (n = 3), and possible pure red cell aplasia (PRCA) (n = 2). Conclusions and Clinical Importance: Darbepoetin, when combined with treatment of comorbidities, is an effective treatment for anemia secondary to CKD in dogs. A dosing interval >q21d was ineffective at maintaining a response to treatment. PRCA was a possible adverse event in 2 of 33 dogs (6%).
| Original language | English (US) |
|---|---|
| Pages (from-to) | 476-485 |
| Number of pages | 10 |
| Journal | Journal of Veterinary Internal Medicine |
| Volume | 31 |
| Issue number | 2 |
| DOIs | |
| State | Published - Mar 1 2017 |
Fingerprint
Keywords
- Erythropoietin
- Iron
- Pure red cell aplasia
- Renal disease
ASJC Scopus subject areas
- veterinary(all)
Cite this
The Use of Darbepoetin to Stimulate Erythropoiesis in the Treatment of Anemia of Chronic Kidney Disease in Dogs. / Fiocchi, E. H.; Cowgill, Larry D; Brown, D. C.; Markovich, J. E.; Tucker, S.; Labato, M. A.; Callan, M. B.
In: Journal of Veterinary Internal Medicine, Vol. 31, No. 2, 01.03.2017, p. 476-485.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - The Use of Darbepoetin to Stimulate Erythropoiesis in the Treatment of Anemia of Chronic Kidney Disease in Dogs
AU - Fiocchi, E. H.
AU - Cowgill, Larry D
AU - Brown, D. C.
AU - Markovich, J. E.
AU - Tucker, S.
AU - Labato, M. A.
AU - Callan, M. B.
PY - 2017/3/1
Y1 - 2017/3/1
N2 - Background: Darbepoetin alfa (darbepoetin) is an erythropoiesis-stimulating agent used for the treatment of anemia secondary to chronic kidney disease (CKD) in dogs, but reports describing response are lacking. Hypothesis/Objectives: To evaluate the effectiveness of darbepoetin in dogs with anemia secondary to CKD, dosing protocols, and adverse events. Animals: Thirty-three client-owned dogs with naturally occurring CKD, including 26 with comorbidities. Methods: Multi-institutional retrospective study. Results: The median starting dosage and highest dosage of darbepoetin administered were 0.5 and 0.8 μg/kg SC once weekly, respectively. Response to treatment was defined as achieving a packed cell volume (PCV) ≥30% or an increase in PCV ≥10%. Twenty-eight of 33 dogs (85%) achieved a PCV ≥30% and 22 of 33 (67%) dogs achieved an increase in PCV ≥10%. Median time to achieve a PCV ≥30% was 29 days. A higher starting dosage was associated with achieving an increase in PCV ≥10% (P =.01). No dog sustained a response at a dosing interval >q21d. Potential adverse events included increased blood pressure requiring treatment (n = 12), seizures (n = 5), vomiting (n = 3), diarrhea (n = 3), and possible pure red cell aplasia (PRCA) (n = 2). Conclusions and Clinical Importance: Darbepoetin, when combined with treatment of comorbidities, is an effective treatment for anemia secondary to CKD in dogs. A dosing interval >q21d was ineffective at maintaining a response to treatment. PRCA was a possible adverse event in 2 of 33 dogs (6%).
AB - Background: Darbepoetin alfa (darbepoetin) is an erythropoiesis-stimulating agent used for the treatment of anemia secondary to chronic kidney disease (CKD) in dogs, but reports describing response are lacking. Hypothesis/Objectives: To evaluate the effectiveness of darbepoetin in dogs with anemia secondary to CKD, dosing protocols, and adverse events. Animals: Thirty-three client-owned dogs with naturally occurring CKD, including 26 with comorbidities. Methods: Multi-institutional retrospective study. Results: The median starting dosage and highest dosage of darbepoetin administered were 0.5 and 0.8 μg/kg SC once weekly, respectively. Response to treatment was defined as achieving a packed cell volume (PCV) ≥30% or an increase in PCV ≥10%. Twenty-eight of 33 dogs (85%) achieved a PCV ≥30% and 22 of 33 (67%) dogs achieved an increase in PCV ≥10%. Median time to achieve a PCV ≥30% was 29 days. A higher starting dosage was associated with achieving an increase in PCV ≥10% (P =.01). No dog sustained a response at a dosing interval >q21d. Potential adverse events included increased blood pressure requiring treatment (n = 12), seizures (n = 5), vomiting (n = 3), diarrhea (n = 3), and possible pure red cell aplasia (PRCA) (n = 2). Conclusions and Clinical Importance: Darbepoetin, when combined with treatment of comorbidities, is an effective treatment for anemia secondary to CKD in dogs. A dosing interval >q21d was ineffective at maintaining a response to treatment. PRCA was a possible adverse event in 2 of 33 dogs (6%).
KW - Erythropoietin
KW - Iron
KW - Pure red cell aplasia
KW - Renal disease
UR - http://www.scopus.com/inward/record.url?scp=85014323312&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85014323312&partnerID=8YFLogxK
U2 - 10.1111/jvim.14681
DO - 10.1111/jvim.14681
M3 - Article
VL - 31
SP - 476
EP - 485
JO - Journal of Veterinary Internal Medicine
JF - Journal of Veterinary Internal Medicine
SN - 0891-6640
IS - 2
ER -